• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nuwellis Inc.

    10/20/22 4:19:50 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NUWE alert in real time by email
    SC 13G 1 sched13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     

     
    Nuwellis, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.0001 per share
     
     
    (Title of Class of Securities)
     

     
    67113Y108
     
     
    (CUSIP Number)
     

     
    October 20, 2022
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
     
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    Delaware
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
    2,550,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    2,550,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,550,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    8.1%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of (i) 2,550,000 common shares, (ii) 1,049,280 shares of Series I Preferred Stock (the “Preferred Stock”) and (iii) 5,398,930 warrants to purchase common shares (“Warrants”); however, due to the conversion limitations of the Preferred Stock and exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Preferred Stock and Warrants is excluded.
    (2) The certificate of designations for the Preferred Stock includes a provision limiting the holder’s ability to convert the Preferred Stock if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.  Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.


     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
     
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    Delaware
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
     
    2,550,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    2,550,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,550,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    8.1%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of (i) 2,550,000 common shares, (ii) 1,049,280 shares of Preferred Stock and (iii) 5,398,930 Warrants; however, due to the conversion limitations of the Preferred Stock and exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Preferred Stock and Warrants is excluded.
    (2) The certificate of designations for the Preferred Stock includes a provision limiting the holder’s ability to convert the Preferred Stock if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.  Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.



     
    1
     
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
     
    2
     
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
     
    (a)            [ ]
     
     
    (b)            [x]
     
    3
     
    SEC Use Only
     
    4
     
    Citizenship or Place of Organization.
     
    United States
     

     
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
     
    5  Sole Voting Power
     
    2,550,000
     
    6  Shared Voting Power
     
    0
     
    7  Sole Dispositive Power
     
    2,550,000
     
    8  Shared Dispositive Power
     
    0

     
    9
     
    Aggregate Amount Beneficially Owned by Each Reporting Person
    2,550,000(1)
     
     
    10
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
     
    11
     
    Percent of Class Represented by Amount in Row (9)*
     
    8.1%(2)
     
     
    12
     
    Type of Reporting Person (See Instructions)
     
    IN
     
     
    (1) The reporting person’s ownership consists of (i) 2,550,000 common shares, (ii) 1,049,280 shares of Preferred Stock and (iii) 5,398,930 Warrants; however, due to the conversion limitations of the Preferred Stock and exercise limitations of the Warrants, the reporting person’s beneficial ownership of the Preferred Stock and Warrants is excluded.
    (2) The certificate of designations for the Preferred Stock includes a provision limiting the holder’s ability to convert the Preferred Stock if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.  Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 4.99% of the Company.




    Item 1.
    (a)
    Name of Issuer
     
     
    Nuwellis, Inc.
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    12988 Valley View Road
    Eden Prairie, MN 55344
     

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •   Lind Global Fund II LP, a Delaware limited partnership;
    •   Lind Global Partners II LLC, a Delaware limited liability company; and
    •   Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
     
    Common Stock, $0.0001 par value per share

    (e)
    CUSIP Number
     
     
    67113Y108
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit

    99.1                  Joint Filing Agreement by and among the Reporting Persons.



    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    October 20, 2022
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton


    Get the next $NUWE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUWE

    DatePrice TargetRatingAnalyst
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Emerson Martin J

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/18/26 4:26:10 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mcdonald David

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/2/26 4:08:18 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Schultz Carisa

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/12/26 4:15:30 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Nuwellis with a new price target

    ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

    7/29/24 7:42:07 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services

    MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services. Nuwellis Chairman and CEO John Erb commented, "We believe CORE IR's integrated communications approach will enable us to more effectively articulate our value proposition to investors, partners, and key stakeholders. As we continue to expand our presence across the medical device and diag

    4/9/26 8:30:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory

    MINNEAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the creation of a dedicated South Texas commercial territory as part of its ongoing effort to strengthen field engagement in key U.S. hospital markets. South Texas is a significant healthcare region with large hospital systems and leading cardiac and critical care programs managing patients with complex fluid balance challenges. By establishing a focused territory, Nuwellis aims to provide more direct clinical support to physicians and care teams evaluating advanced fluid management strategies

    4/7/26 8:30:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone

    MINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces continued momentum in its pediatric category, which is now the Company's largest and fastest-growing category and represents approximately 50% of total U.S. revenue. "Our pediatric category has become a meaningful and durable driver of growth, now accounting for approximately half of total revenue in 2025. This is a significant milestone as it both demonstrates the importance of the pediatric utilization of Aquadex, and the flexibility of the device across multiple patient demographics," said Nuwell

    3/31/26 8:30:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    SEC Filings

    View All

    SEC Form DEFA14A filed by Nuwellis Inc.

    DEFA14A - Nuwellis, Inc. (0001506492) (Filer)

    4/6/26 4:30:41 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEF 14A filed by Nuwellis Inc.

    DEF 14A - Nuwellis, Inc. (0001506492) (Filer)

    4/2/26 5:01:21 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - Nuwellis, Inc. (0001506492) (Filer)

    4/1/26 4:45:27 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025

    MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that it will release financial results for the third quarter 2025 on November 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-274-8461 (U.S) or 1-203-51

    10/23/25 9:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    8/30/24 4:11:06 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    8/2/24 4:12:11 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    5/6/24 4:01:02 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care